Table 2.

Influence of discontinuation or continuation of antihypertensive drugs on KCL score in 78 patients who attended the frailty clinic at the National Center for Geriatrics and Gerontology, Obu, Japan.

KCL domain	Discontinuation (n = 19)	Continuation (n = 59)	Statistical significance
IADL
First visit	1 (0–4)	1 (0–4)	P = 0.40‡
1-year follow-up visit	1 (0–3)	1 (0–5)	P = 0.69‡
Statistical significance	P = 0.64†	P = 0.30†
Physical strength
First visit	3 (1–5)	3 (0–5)	P = 0.27‡
1-year follow-up visit	2 (0–4)	3 (0–5)	P = 0.51‡
Statistical significance	P < 0.05†	P = 0.20†
Nutrition
First visit	0 (0–2)	0 (0–1)	P = 0.53‡
1-year follow-up visit	0 (0–2)	0 (0–1)	P = 0.61‡
Statistical significance	P = 0.22†	P = 0.08†
Oral function
First visit	1 (0–3)	1 (0–3)	P = 0.64‡
1-year follow-up visit	1 (0–3)	1 (0–3)	P = 0.98‡
Statistical significance	P = 0.75†	P = 0.67†
Isolation
First visit	1 (0–2)	0 (0–2)	P = 0.49‡
1-year follow-up visit	0 (0–1)	0 (0–2)	P = 0.89‡
Statistical significance	P < 0.05†	P < 0.05†
Memory
First visit	0 (0–3)	0 (0–2)	P = 0.72‡
1-year follow-up visit	0 (0–2)	0 (0–2)	P = 0.54‡
Statistical significance	P = 0.18†	P = 0.20†
Mood
First visit	2 (0–4)	2 (0–3)	P = 0.78‡
1-year follow-up visit	0 (0–5)	1 (0–2)	P = 0.17‡
Statistical significance	P = 0.26†	P < 0.01†
Total score
First visit	8 (1–20)	7 (1–19)	P = 0.74‡
1-year follow-up visit	6 (1–14)	5 (0–17)	P = 0.64‡
Statistical significance	P < 0.05†	P < 0.01†

Data presented as median (range).

IADL, instrumental activities of daily living.

†Wilcoxon signed–rank test; ‡Wilcoxon rank-sum test.